Zelboraf
FDA approves Roche skin cancer combination
November 11, 2015Research and Development, Sales and Marketing Cotellic, FDA, Genentech, Roche, Zelboraf, cobimetinib, melanoma, skin cancer, vemurafenib
The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …
Roche submits melanoma drug to FDA
December 15, 2014Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib
Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …
GSK melanoma drugs beat rival in new study
July 18, 2014Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma
GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …
Eight in ten survive skin cancer
July 22, 2013Research and Development, Sales and Marketing Yervoy, Zelboraf, melanoma, skin cancer
The vast majority of men and women diagnosed with malignant melanoma are now surviving the disease, according to a new …
Roche’s Erivedge gains conditional EU approval
July 15, 2013Sales and Marketing Curis, EU, Erivedge, Roche, Swiss, Zelboraf
Roche’s cancer pill Erivedge has received a conditional European approval for treatment of the most common type of skin cancer. …
NICE hails ‘breakthrough’ skin cancer treatments
November 2, 2012Sales and Marketing BMS, NICE, Roche, Yervoy, Zelboraf
Two new skin cancer drugs have been recommended by NICE, which hailed the drugs as ‘breakthrough treatments’. Bristol-Myers Squibb’s Yervoy …
BMS highlights Yervoy survival data
October 1, 2012Research and Development, Sales and Marketing BMS, Roche, Yervoy, Zelboraf
Bristol-Myers Squibb’s melanoma drug Yervoy helps patients survive for longer than if they are receiving standard chemotherapy alone, according to …
NICE still minded not to recommend Zelboraf
August 9, 2012Sales and Marketing BMS, NICE, QALY, Yervoy, Zelboraf
NICE is asking Roche for more information about its melanoma pill Zelboraf, saying it is still too expensive and its …
GSK submits melanoma drugs for regulatory approval
August 3, 2012Sales and Marketing FDA, GSK, NDA, Zelboraf, melanoma, oncology
GlaxoSmithKline has submitted its two investigational melanoma drugs to regulators in both Europe and the US. The firm is seeking …
Roche posts strong sales results
July 27, 2012Sales and Marketing Pegasys, Perjeta, Roche, Zelboraf, dalcetrapib
Roche has published healthy revenue growth for the first half of 2012, but its profits have taken a hit. The …
Roche’s Zelboraf rejected by NICE
June 15, 2012Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma
NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …
GSK starts combination trial for melanoma
May 30, 2012Research and Development, Sales and Marketing GSK, R&D, Roche, Zelboraf, melanoma
GlaxoSmithKline has begun a combination trial for two of its investigational skin cancer drugs. The firm will combine dabrafenib, its …
Roche’s melanoma pill launched in UK
March 14, 2012Sales and Marketing BMS, CDF, NICE, Roche, Yervoy, Zelboraf
Roche’s Zelboraf has been launched in the UK to treat the deadliest form of skin cancer. Zelboraf (vemurafenib) is the …
Major new drugs for 2012
March 9, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Caprelsa, Eylea, Manjor new drugs, Xalkori, Zelboraf, avastin, inlyta
Renal cell carcinoma Pfizer’s Inlyta (axitinib) has been approved as second line treatment for renal cell carcinoma. The drug is …
Latest content
FibroFind appoints Lee Borthwick as CEO
